<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE328nnn/GSE328664/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Other</omics_type><species>Homo sapiens</species><gds_type>Other</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE328664</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>PD-1 regulates latent effector differentiation of thymic cytotoxic CD8+ T cells</name><description>Durable T cell immunity against cancer depends on the continual replenishment of effector CD8⁺ T cells. Thymic output has been associated with favorable prognosis in cancer patients across a range of ages, suggesting that the thymus is an important source for replenishing T cells capable of controlling cancer progression. However, whether CD8⁺ T cells acquire effector potential within the thymus, and how thymic output of effector CD8⁺ T cells contribute to peripheral tumor immunity, remain unclear. In this study, we discover that thymic single-positive (SP) CD8⁺ T cells undergo latent effector differentiation following thymic selection, but this process is subject to PD-1 regulation. We further demonstrate that PD-1 limits the contribution of thymic output of CD8⁺ T cells in shaping the TCR repertoire within the tumor tissues for tumor immunosurveillance. Although PD-1 inhibition facilitates the expansion of effector CD8⁺ T cells in the periphery, these cells gradually lose antitumor activity within tumors due to accelerated exhaustion in the absence of PD-1. Thus, while latent effector differentiation of thymic CD8⁺ T cells enable a rapid response to malignant cells in the periphery, PD-1 restrains this process to prevent overt or terminal effector differentiation, which could compromise balanced and durable peripheral immunity.</description><dates><publication>2026/05/01</publication></dates><accession>GSE328664</accession><cross_references><GSM>GSM9686914</GSM><GSM>GSM9686915</GSM><GSM>GSM9686916</GSM><GSM>GSM9686917</GSM><GSM>GSM9686918</GSM><GSM>GSM9686919</GSM><GSM>GSM9686886</GSM><GSM>GSM9686920</GSM><GSM>GSM9686887</GSM><GSM>GSM9686921</GSM><GSM>GSM9686888</GSM><GSM>GSM9686889</GSM><GSM>GSM9686922</GSM><GSM>GSM9686923</GSM><GSM>GSM9686924</GSM><GSM>GSM9686903</GSM><GSM>GSM9686904</GSM><GSM>GSM9686905</GSM><GSM>GSM9686906</GSM><GSM>GSM9686907</GSM><GSM>GSM9686908</GSM><GSM>GSM9686909</GSM><GSM>GSM9686910</GSM><GSM>GSM9686911</GSM><GSM>GSM9686912</GSM><GSM>GSM9686913</GSM><GSM>GSM9686936</GSM><GSM>GSM9686937</GSM><GSM>GSM9686938</GSM><GSM>GSM9686939</GSM><GSM>GSM9686940</GSM><GSM>GSM9686941</GSM><GSM>GSM9686942</GSM><GSM>GSM9686943</GSM><GSM>GSM9686900</GSM><GSM>GSM9686944</GSM><GSM>GSM9686901</GSM><GSM>GSM9686945</GSM><GSM>GSM9686902</GSM><GSM>GSM9686925</GSM><GSM>GSM9686926</GSM><GSM>GSM9686927</GSM><GSM>GSM9686928</GSM><GSM>GSM9686929</GSM><GSM>GSM9686890</GSM><GSM>GSM9686891</GSM><GSM>GSM9686892</GSM><GSM>GSM9686893</GSM><GSM>GSM9686894</GSM><GSM>GSM9686895</GSM><GSM>GSM9686896</GSM><GSM>GSM9686897</GSM><GSM>GSM9686930</GSM><GSM>GSM9686931</GSM><GSM>GSM9686898</GSM><GSM>GSM9686932</GSM><GSM>GSM9686899</GSM><GSM>GSM9686933</GSM><GSM>GSM9686934</GSM><GSM>GSM9686935</GSM><GPL>34281</GPL><GSE>328664</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>